Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS). The therapy, STP144G, is one of four experimental treatments developed with the proprietary Sirnaomics platform. Data from these early studies are expected to eventually…